The store will not work correctly when cookies are disabled.
We use cookies for optimal website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.
Allow cookies Deny
Desmorpholinyl Navitoclax-NH-Me; (R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-(methylamino)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; CAS No.: 2365172-82-1; Desmorpholinyl Navitoclax-NH-Me. PROPERTIES: Desmorpholinyl Navitoclax-NH-Me is a small molecule inhibitor appearing as a white to pale yellow solid. This compound has a molecular weight of approximately 400-500 g/mol. It is moderately soluble in DMSO and dimethylformamide but has limited water solubility. Desmorpholinyl Navitoclax-NH-Me should be stored at -20 C in a tightly sealed container to maintain stability. It is sensitive to moisture and light. Safety precautions include avoiding skin and eye contact as it may cause irritation. APPLICATIONS: Desmorpholinyl Navitoclax-NH-Me is used in cancer research as a potent inhibitor of BCL-2 family proteins. It facilitates the study of apoptosis regulation in various cancer cell lines. In pharmacology, it serves as a tool to investigate the mechanisms of chemoresistance. In preclinical models, Desmorpholinyl Navitoclax-NH-Me demonstrates antiproliferative effects and is studied for potential therapeutic applications. These applications are reported in oncology research papers and apoptosis signaling literature.